With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

BAE Systems (LON: BA) has invested more than $260 million in its facilities over the past six years to increase support to ...

Merus leads biotech with its innovative antibody platforms, strong financials, and promising petosemtamab targeting cancer.

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Regarding myeloma, Burke also shares his experience with myeloma BsAbs, saying, “I follow the drug label, administer the drug ...

Notably, our first-in-class bispecific antibodies, cadonilimab and ivonescimab, have been approved for commercial sales and included in China's NRDL. This significantly improves drug accessibility ...

a first-in-class PD-1/IL-2a-bias bispecific antibody fusion protein, as monotherapy for the treatment of unresectable locally advanced or metastatic mucosal or acral melanoma who have not received ...

IBI363 is a first-in-class drug candidate independently developed by Innovent Biologics. It is a PD-1/IL-2 bispecific antibody fusion protein designed to enhance efficiency while minimizing toxicity.

antibody drug conjugates (“ADCs”) and bispecific ADCs. The company also achieved major milestones in commercialization and patient access, with products included in national insurance directories.

Because immunoglobulins are matched to a specific pathogen, they can be used to diagnose some diseases based on their unique structure. Antibody tests are used to detect disease-specific antibodies in ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Compass Therapeutics, Inc. (NASDAQ:CMPX) stands against other hot biotech stocks ...

To date, the Food and Drug Administration (FDA) has approved seven chimeric antigen receptor-T (CAR-T) cell therapies and seven bispecific T-cell engagers (BiTEs) across a variety of hematologic ...